Table II.
Proportion of study participants meeting various CRS symptom and radiologic opacification definitions in study sample (unweighted) and as estimated prevalence in source population (native weights)
| Characteristic | Study Sample (n = 646) Unweighted Percent (SE) | Source Population Weighted† Percent (SE) |
|---|---|---|
| CRSS status‡ | ||
| Current (n = 324) | 50.2 (2.0) | 16.1 (1.9) |
| Past (n = 249) | 38.5 (1.9) | 24.5 (1.8) |
| Never (n = 73) | 11.3 (1.2) | 59.5 (2.0) |
| CRSO status§ | ||
| Lund-Mackay ≥ 3 (n = 168) | 26.0 (1.7) | 12.4 (2.3) |
| Lund-Mackay ≥ 4 (n = 137) | 21.2 (1.6) | 11.2 (2.3) |
| Lund-Mackay ≥ 6 (n = 89) | 13.8 (1.4) | 6.6 (1.9) |
| CRSS-O status¶ | ||
| Lund-Mackay ≥ 3 (n = 89) | 13.8 (1.4) | 3.6 (0.80) |
| Lund-Mackay ≥ 4 (n = 73) | 11.3 (1.2) | 3.2 (0.79) |
| Lund-Mackay ≥ 6 (n = 41) | 6.3 (0.96) | 1.3 (0.67) |
| Frontal sinus opacification¥ | 13.0 (1.3) | 8.3 (2.5) |
| Maxillary sinus opacification¥ | 42.6 (1.9) | 28.6 (7.1) |
| Anterior ethmoid opacitication¥ | 28.8 (1.8) | 21.7 (7.1) |
| Posterior ethmoid opacification¥ | 19.4 (1.6) | 14.7 (6.7) |
| Sphenoid opacification¥ | 9.9 (1.2) | 5.1 (1.7) |
| Ostiomeatal complex opacification¥ | 12.9 (1.3) | 8.1 (2.2) |
| Nasal cavity opacification¥ | 5.3 (0.88) | 1.6 (0.48) |
†
Weighted for sampling and participation rates to estimate prevalence in source population.
‡
Never: did not report European Position Paper on Rhinosinusitis (EPOS) CRS symptoms in lifetime; past: met EPOS CRS symptoms in lifetime but not currently; current: met EPOS CRS symptoms in the last 3 months.
§
Lund-Mackay score based on CT scoring by two otolaryngologists blinded to CRSS status.
¶
Met criteria for current CRSS and CRSO criteria at different Lund-Mackay cut-points.
¥
Any opacification/occlusion score >0.